BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim MN, Kim BK, Han K, Kim SU. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Review of Gastroenterology & Hepatology 2014;9:335-48. [DOI: 10.1586/17474124.2015.959929] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Son MH, Ha LN, Bang MH, Bae S, Giang DT, Thinh NT, Paeng JC. Diagnostic and prognostic value of 99mTc-MAA SPECT/CT for treatment planning of 90Y-resin microsphere radioembolization for hepatocellular carcinoma: comparison with planar image. Sci Rep 2021;11:3207. [PMID: 33547398 DOI: 10.1038/s41598-021-82887-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Chapman WC, Korenblat KM, Fowler KJ, Saad N, Khan AS, Subramanian V, Doyle MBM, Dageforde LA, Tan B, Grierson P, Lin Y, Xu M, Brunt EM. Hepatocellular carcinoma: Where are we in 2018? Curr Probl Surg 2018;55:450-503. [PMID: 30526875 DOI: 10.1067/j.cpsurg.2018.10.002] [Reference Citation Analysis]
3 Patella F, Pesapane F, Fumarola E, Zannoni S, Brambillasca P, Emili I, Costa G, Anderson V, Levy EB, Carrafiello G, Wood BJ. Assessment of the response of hepatocellular carcinoma to interventional radiology treatments. Future Oncol 2019;15:1791-804. [PMID: 31044615 DOI: 10.2217/fon-2018-0747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Aujay G, Etchegaray C, Blanc J, Lapuyade B, Papadopoulos P, Pey M, Bordenave L, Trillaud H, Saut O, Pinaquy J. Comparison of MRI-based response criteria and radiomics for the prediction of early response to transarterial radioembolization in patients with hepatocellular carcinoma. Diagnostic and Interventional Imaging 2022. [DOI: 10.1016/j.diii.2022.01.009] [Reference Citation Analysis]
5 Aprile G, Fontanella C, Bonotto M, Rihawi K, Lutrino SE, Ferrari L, Casagrande M, Ongaro E, Berretta M, Avallone A, Rosati G, Giuliani F, Fasola G. Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. Oncotarget 2015;6:28716-30. [PMID: 26308250 DOI: 10.18632/oncotarget.4747] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
6 Langenbach MC, Vogl TJ, Said G, Scholtz JE, Hammerstingl R, Gruber-Rouh T. Lipiodol as a Predictive Indicator for Therapy Response to Transarterial Chemoembolization of Hepatocellular Carcinoma. Cancer Biother Radiopharm 2021. [PMID: 33481646 DOI: 10.1089/cbr.2020.4137] [Reference Citation Analysis]
7 Liu B, Zhang Y, Chen H, Li W, Tsochatzis E. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma. Cochrane Database Syst Rev 2022;1:CD013345. [PMID: 34981511 DOI: 10.1002/14651858.CD013345.pub2] [Reference Citation Analysis]
8 Lock M, Malayeri AA, Mian OY, Mayr NA, Herman JM, Lo SS. Computed tomography imaging assessment of postexternal beam radiation changes of the liver. Future Oncol 2016;12:2729-39. [PMID: 27576360 DOI: 10.2217/fon-2016-0165] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ippolito D, Querques G, Okolicsanyi S, Franzesi CT, Strazzabosco M, Sironi S. Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study. Eur J Radiol 2017;90:34-41. [PMID: 28583645 DOI: 10.1016/j.ejrad.2017.02.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
10 Schoenberg M, Khandoga A, Stintzing S, Trumm C, Schiergens TS, Angele M, Op den Winkel M, Werner J, Muacevic A, Rentsch M. CyberKnife Radiosurgery - Value as an Adjunct to Surgical Treatment of HCC? Cureus 2016;8:e591. [PMID: 27284498 DOI: 10.7759/cureus.591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Li H, Liu J, Chen M, Li H, Long L. Therapeutic Evaluation of Radiotherapy with Contrast-Enhanced Ultrasound in Non-Resectable Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis. Med Sci Monit 2018;24:8183-9. [PMID: 30426970 DOI: 10.12659/MSM.911073] [Reference Citation Analysis]
12 Wasnik AP. Tumor Response Criteria-Radiological Implications. Acad Radiol 2018;25:1361-2. [PMID: 30122626 DOI: 10.1016/j.acra.2018.07.011] [Reference Citation Analysis]
13 Henze J, Maintz D, Persigehl T. RECIST 1.1, irRECIST 1.1, and mRECIST: How to Do. Curr Radiol Rep 2016;4. [DOI: 10.1007/s40134-016-0178-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
14 Senk K, Wilcke J, Haimerl M, Verloh N, Rio Bartulos C, Bäumler W, Stroszczynski C, Wiggermann P. Prediction of transarterial chemoembolization (TACE) outcome by pre- and postinterventional 13C-methacetin breath test. Clin Hemorheol Microcirc 2021;79:73-80. [PMID: 34487035 DOI: 10.3233/CH-219118] [Reference Citation Analysis]
15 Arslanoglu A, Seyal AR, Sodagari F, Sahin A, Miller FH, Salem R, Yaghmai V. Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review. American Journal of Roentgenology 2016;207:W88-98. [DOI: 10.2214/ajr.15.15490] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
16 Frakes JM, Abuodeh YA, Naghavi AO, Echevarria MI, Shridhar R, Friedman M, Kim R, El-Haddad G, Kis B, Biebel B, Sweeney J, Choi J, Anaya D, Giuliano AR, Hoffe SE. Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolization. J Gastrointest Oncol 2018;9:546-52. [PMID: 29998020 DOI: 10.21037/jgo.2018.03.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Berretta M, Rinaldi L, Di Benedetto F, Lleshi A, De Re V, Facchini G, De Paoli P, Di Francia R. Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. Front Pharmacol 2016;7:428. [PMID: 27881963 DOI: 10.3389/fphar.2016.00428] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
18 Lee JS, Lee HA, Jeon MY, Lim TS, Kim BK, Park JY, Kim DY, Ahn SH, Um SH, Han K, Seo YS, Kim SU. Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. European Journal of Gastroenterology & Hepatology 2020;32:739-47. [DOI: 10.1097/meg.0000000000001585] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Schicho A, Pereira PL, Pützler M, Michalik K, Albrecht T, Nolte-Ernsting C, Stroszczynski C, Wiggermann P. Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in Intrahepatic Cholangiocellular Carcinoma (ICC): Results from a National Multi-Center Study on Safety and Efficacy. Med Sci Monit 2017;23:796-800. [PMID: 28192388 DOI: 10.12659/msm.902901] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
20 Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers (Basel) 2020;12:E1914. [PMID: 32679897 DOI: 10.3390/cancers12071914] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
21 Pang J, Hao G, Chen Y. Clinical effects and prognosis of stereotactic body radiotherapy combined with transarterial chemoembolization for massive hepatocellular carcinoma. Prec Radiat Oncol 2021;5:12-7. [DOI: 10.1002/pro6.1111] [Reference Citation Analysis]
22 Makary MS, Ramsell S, Miller E, Beal EW, Dowell JD. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons. World J Gastroenterol 2021; 27(43): 7462-7479 [PMID: 34887643 DOI: 10.3748/wjg.v27.i43.7462] [Reference Citation Analysis]
23 Schicho A, Pereira PL, Haimerl M, Niessen C, Michalik K, Beyer LP, Stroszczynski C, Wiggermann P. Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy. Oncotarget 2017;8:72613-20. [PMID: 29069813 DOI: 10.18632/oncotarget.19997] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Tudela-lerma M, Orcajo-rincón J, Ramón-botella E, Álvarez-luque A, Gonzalez-leyte M, Rotger-regi A, Velasco-sánchez E, Colón-rodriguez A. Efficacy and safety of Yttrium-90 radioembolization in the treatment of neuroendocrine liver metastases. Long-term monitoring and impact on survival. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2021;40:82-90. [DOI: 10.1016/j.remnie.2021.01.009] [Reference Citation Analysis]
25 Serra C, Cucchetti A, Felicani C, Mosconi C, De Cinque A, Golfieri R, Andreone P, Ercolani G, Maroni L, Ravaioli M, D'Errico A, Pinna AD, Cescon M. Assessment of Radiofrequency Ablation Efficacy for Hepatocellular Carcinoma by Histology and Pretransplant Radiology. Liver Transpl 2019;25:88-97. [PMID: 30415500 DOI: 10.1002/lt.25381] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
26 Schicho A, Pereira PL, Michalik K, Beyer LP, Stroszczynski C, Wiggermann P. Safety and efficacy of transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in the treatment of secondary liver malignancies. Onco Targets Ther 2018;11:345-50. [PMID: 29391811 DOI: 10.2147/OTT.S147852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
27 Bastiaannet R, Kappadath SC, Kunnen B, Braat AJAT, Lam MGEH, de Jong HWAM. The physics of radioembolization. EJNMMI Phys 2018;5:22. [PMID: 30386924 DOI: 10.1186/s40658-018-0221-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
28 Crombé A, Kind M, Ray-Coquard I, Isambert N, Chevreau C, André T, Lebbe C, Cesne AL, Bompas E, Piperno-Neumann S, Saada E, Bouhamama A, Blay JY, Italiano A; French Sarcoma Group. Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma Group. AJR Am J Roentgenol 2020;215:1539-48. [PMID: 32991215 DOI: 10.2214/AJR.19.22635] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
29 Choi MH, Park GE, Oh SN, Park MY, Rha SE, Lee YJ, Jung SE, Choi JI. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization. Acad Radiol 2018;25:1363-73. [PMID: 29555570 DOI: 10.1016/j.acra.2018.02.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
30 Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han K, Baek S, Kim HS, Kim SU, Park MS. Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib. Liver Int 2018;38:1655-63. [DOI: 10.1111/liv.13731] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
31 Tudela-Lerma M, Orcajo-Rincón J, Ramón-Botella E, Álvarez-Luque A, González-Leyte M, Rotger-Regi A, Velasco-Sánchez E, Colón-Rodríguez A. Efficacy and safety of Yttrium-90 radioembolization in the treatment of neuroendocrine liver metastases. Long-term monitoring and impact on survival. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021;40:82-90. [PMID: 33239249 DOI: 10.1016/j.remn.2020.09.002] [Reference Citation Analysis]
32 Zhen Y, Liu B, Chang Z, Ren H, Liu Z, Zheng J. A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma. Onco Targets Ther 2019;12:4489-98. [PMID: 31239717 DOI: 10.2147/OTT.S202875] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
33 van Lunenburg JTJ, Tripathi V, Chan VSH, Lee VKH, Lee EY, Vardhanabhuti V, Chiu KWH. Sequence and Observer Variability in Gadoxectic Acid-Enhanced MRI Lesion Measurements in Hepatocellular Carcinoma. Acad Radiol 2020;27:e64-71. [PMID: 31326308 DOI: 10.1016/j.acra.2019.05.021] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Lee JS, Chon YE, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kang W, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Kim HY, Kim TH, Yoo K, Ha Y, Kim MN, Lee JH, Hwang SG, Kim SS, Cho HJ, Cheong JY, Cho SW, Park SH, Heo NY, Hong YM, Yoon KT, Cho M, Park JG, Kang MK, Park SY, Kweon YO, Tak WY, Jang SY, Sinn DH, Kim SU; Korean TACE Study Group. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. Yonsei Med J 2021;62:12-20. [PMID: 33381930 DOI: 10.3349/ymj.2021.62.1.12] [Reference Citation Analysis]
35 Cohen NA, Kim TS, DeMatteo RP. Principles of Kinase Inhibitor Therapy for Solid Tumors. Ann Surg 2017;265:311-9. [PMID: 27058947 DOI: 10.1097/SLA.0000000000001740] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
36 Lee JS, Choi HJ, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Baek SE, Chung YE, Park MS, Kim MJ, Rhee H, Kim SU. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. Gut Liver 2020;14:765-74. [PMID: 32050313 DOI: 10.5009/gnl19197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
37 Pinker K, Riedl C, Weber WA. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur J Nucl Med Mol Imaging. 2017;44:55-66. [PMID: 28361188 DOI: 10.1007/s00259-017-3687-3] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 12.2] [Reference Citation Analysis]
38 Mazzeo S, Cervelli R, Elisei R, Tarantini G, Cappelli C, Molinaro E, Galleri D, De Napoli L, Comite C, Cioni R, Vitti P, Caramella D. mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study. J Endocrinol Invest 2018;41:1389-99. [PMID: 29687416 DOI: 10.1007/s40618-018-0886-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
39 Ding X, Sun W, Chen J, Li W, Shen Y, Guo X, Teng Y, Liu X, Sun S, Wei J, Li W, Chen H, Liu B. Percutaneous Radiofrequency Ablation Combined With Transarterial Chemoembolization Plus Sorafenib for Large Hepatocellular Carcinoma Invading the Portal Venous System: A Prospective Randomized Study. Front Oncol 2020;10:578633. [PMID: 33194699 DOI: 10.3389/fonc.2020.578633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
40 Feng Y, Wang L, Lv H, Shi T, Xu C, Zheng H, Qi J, Zhao X, Li J, Gao Y, Qin C, Zhu Q. Microwave ablation versus radiofrequency ablation for perivascular hepatocellular carcinoma: a propensity score analysis. HPB (Oxford) 2021;23:512-9. [PMID: 32839089 DOI: 10.1016/j.hpb.2020.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]